[1] Gholivand K., Pourayoubi M., Shariatinia Z., “2,3J(P,X) [X=H, C] coupling constants dependency on the ring size, hybridization and substituents in new diazaphospholes and diazaphosphorinanes, NMR and X-ray crystallography studies”, Polyhedron 26 (2007) 837–844. https://doi.org/10.1016/j.poly.2006.09.092.
[2] Gholivand K., Ghaziani F., Shariatinia Z., Dorosti N., Mirshahi M., Sarikhani S., “Antitumor activities of some new 1,3,2-oxaza- and 1,3,2-diazaphosphorinanes against K562, MDA-MB-231, and HepG2 cells”, Medicinal Chemistry Research 21 (2012) 2185–2195. https://doi.org/10.1007/s00044-011-9737-7.
[3] Varshney L., Dodke P.B., “Radiation effect studies on anticancer drugs, cyclophosphamide and doxorubicin for radiation sterilization”, Radiation Physics and Chemistry 71 (2004) 1103–1111. https://doi.org/10.1016/j.radphyschem.2003.12.052.
[4] Baumann F., Preiss R., “Cyclophosphamide and related anticancer drugs”, Journal of Chromatography B: Biomedical Sciences and Applications 764 (2001) 173–192. https://doi.org/10.1016/S0378-4347(01)00279-1.
[5] Ishida T., Shiraga E., Kiwada H., “Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model”, Journal of Controlled Release 134 (2009) 194–200. https://doi.org/10.1016/j.jconrel.2008.11.019.
[6] Delahousse J., Molina L., Paci A., “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”, Cancer Letters 598 (2024) 217119. https://doi.org/10.1016/j.canlet.2024.217119.
[7] Carter T.J., Milic M., McDerra J., McTiernan A., Ahmed M., Karavasilis V., Michelagnoli M., Windsor R., Seddon B., Whelan J., Dileo P., Strauss S.J., “Continuous 14 day infusional ifosfamide for management of soft-tissue and bone sarcoma: a single centre retrospective cohort analysis”, Cancers (Basel) 12 (2020) 3408. https://doi.org/10.3390/cancers12113408.
[8] Borch R.F., Canute G.W., “Synthesis and antitumor properties of activated cyclophosphamide analogues”, Journal of Medicinal Chemistry 34 (1991) 3044–3052. https://doi.org/10.1021/jm00114a013.
https://doi.org/10.5604/17322693.1079389.
https://doi.org/10.1080/10426507.2012.743547.
[9] Al-Wahaibi L.H., Macías M.A., Blacque O., Zondagh L.S., Joubert J., Thamotharan S., Percino M.J., Mohamed A.A.B., El-Emam A.A., “Weak noncovalent interactions in three closely related adamantane-linked 1,2,4-triazole N-mannich bases: insights from energy frameworks, Hirshfeld surface analysis, in silico 11β-HSD1 molecular docking and ADMET prediction”, molecules 27 (2022) 7403. https://doi.org/10.3390/molecules27217403.
[10] Kıncal S., Topkaya C., Hökelek T., Çetin E.S., Güp R., “Synthesis, crystal structure and Hirshfeld surface analyses, crystal voids, interaction energy calculations and energy frameworks and biological studies of oxime barbiturate derivatives”, Journal of Molecular Structure 1302 (2024) 137451. https://doi.org/10.1016/j.molstruc.2023.137451.
https://doi.org/10.1107/S2053273314026370.
[11] Yang L., Powell D.R., Houser R.P., “Structural variation in copper(I) complexes with pyridylmethylamide ligands: structural analysis with a new four-coordinate geometry index, τ4”, Dalton Trans. (2007) 955–964. https://doi.org/10.1039/b617136b.
[12] Corbridge, D.E.C. (2013). Phosphorus: Chemistry, Biochemistry and Technology (6th ed.). CRC Press, Boca Raton, FL, USA (2013).
[13] Cremer D., Pople J.A., “A General definition of ring puckering coordinates”, Journal of the American Chemical Society 97 (1975) 1354–1358. https://doi.org/10.1021/ja00839a011.
[14] Spackman P.R., Turner M.J., McKinnon J.J., Wolff S.K., Grimwood D.J., Jayatilaka D., Spackman M.A., “CrystalExplorer : a program for Hirshfeld surface analysis, visualization and quantitative analysis of molecular crystals”, Journal of Applied Crystallography 54 (2021) 1006–1011. https://doi.org/10.1107/S1600576721002910.
[15] Murray J.S., Politzer P., “The electrostatic potential: An overview”, Wiley Interdiscip Computational Molecular Science 1 (2011) 153–163. https://doi.org/10.1002/WCMS.19.
[16] Frisch M.J., “GAUSSIAN09”, Gaussian Inc, Wallingford, CT, USA, (2009) http://www.gaussian.com.